Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer?

M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659–1672.

Jason M. Kaplan Department of Medical Oncology, Royal North Shore Hospital Sydney and Sydney Haematology and Oncology Clinics, NSW, Australia

Gavin Marx Department of Medical Oncology, Royal North Shore Hospital Sydney and Sydney Haematology and Oncology Clinics, NSW, Australia

References

Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005353:1652-1654
PubMed Web of Science ®Google Scholar
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659–1672
Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792
PubMed Web of Science ®Google Scholar
Hortobagyi ON. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734–1736
PubMed Web of Science ®Google Scholar
Romond EH, et al. Trastuzumab plus adjuvant chemo-therapy for operable HER2-positive breast cancer. N Engl J Med 2005353:1673-1684
PubMed Web of Science ®Google Scholar
Dent R, Clemons M. Adjuvant trastuzumab for breast cancer BMJ 2005;331:1035–1036
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer?

M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659–1672.

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer?

M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659–1672.

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date